Wanjia Group Holdings Ltd. (HK:0401)
:0401
Top Page
Wanjia Group Holdings Ltd.
(0401)
Select Model
Select Model
Rating:54Neutral
Price Target:
HK$0.13
▲(43.33% Upside)
Action:ReiteratedDate:03/24/26
The score is held back primarily by weak and recently negative profitability (loss-making results driving a negative P/E). This is partially offset by solid recent cash generation and a conservatively levered balance sheet, while technical indicators are moderately positive but not strongly trending.
Positive Factors
Conservative leverage
A low debt-to-equity (~0.18) provides structural financial flexibility, reducing default and refinancing risk during weak earnings periods. This conservative capital structure supports ongoing operations, funds working-capital needs, and preserves capacity for strategic investments or acquisitions over the medium term.
Negative Factors
Weak profitability
Sustained accounting losses and negative operating margins through FY2024–FY2025 undermine the company's ability to compound equity and fund strategic initiatives internally. Persistent operating losses suggest structural issues in cost control, pricing, or channel economics that could limit long-term value creation if unresolved.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative leverage
A low debt-to-equity (~0.18) provides structural financial flexibility, reducing default and refinancing risk during weak earnings periods. This conservative capital structure supports ongoing operations, funds working-capital needs, and preserves capacity for strategic investments or acquisitions over the medium term.
Read all positive factors
Wanjia Group Holdings Ltd. (0401) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$126.61M
Dividend YieldN/A
Average Volume (3M)589.99K
Price to Earnings (P/E)―
Beta (1Y)0.33
Revenue Growth-4.50%
EPS Growth75.98%
CountryHK
Employees155
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,120,444,200
10 Day Avg. Volume1,113,336
30 Day Avg. Volume589,992
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.70
Price to Sales (P/S)0.29
P/FCF Ratio4.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Wanjia Group Holdings Ltd. Business Overview & Revenue Model
Company Description
Wanjia Group Holdings Limited, an investment holding company, engages in pharmaceutical wholesale and distribution business in the People's Republic of China and Hong Kong. It also offers hemodialysis treatment and consultancy services. The compan...
How the Company Makes Money
The company primarily generates revenue through the sale of its healthcare and consumer goods products, including traditional Chinese medicine and over-the-counter remedies. It earns income by distributing these products to retail clients and whol...
Wanjia Group Holdings Ltd. Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
64
Positive
Cash Flow
72
Positive
| Breakdown | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 161.69M | 181.09M | 173.70M | 154.82M | 114.09M |
| Gross Profit | 50.35M | 54.74M | 56.94M | 54.23M | 41.34M |
| EBITDA | 4.13M | -29.02M | 16.40M | -34.64M | 8.16M |
| Net Income | -6.62M | -39.98M | 1.82M | -51.00M | -4.54M |
Balance Sheet | |||||
| Total Assets | 106.82M | 117.10M | 173.45M | 191.82M | 223.59M |
| Cash, Cash Equivalents and Short-Term Investments | 24.08M | 18.23M | 9.88M | 5.77M | 25.10M |
| Total Debt | 11.72M | 15.60M | 25.17M | 24.49M | 29.17M |
| Total Liabilities | 38.19M | 41.91M | 53.22M | 63.72M | 52.51M |
| Stockholders Equity | 66.88M | 73.49M | 118.20M | 126.18M | 169.31M |
Cash Flow | |||||
| Free Cash Flow | 9.92M | 5.89M | 5.47M | -4.86M | -4.34M |
| Operating Cash Flow | 10.65M | 9.30M | 9.38M | 2.12M | 7.61M |
| Investing Cash Flow | -697.00K | 674.00K | -3.84M | -6.93M | -11.84M |
| Financing Cash Flow | -3.71M | -1.04M | -802.00K | -14.97M | 4.33M |
Wanjia Group Holdings Ltd. Technical Analysis
Neutral
0.09
Price Trends
0.11
Positive
0.10
Positive
0.09
Positive
Market Momentum
<0.01
Positive
45.92
Neutral
63.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0401, the sentiment is Neutral. The current price of 0.09 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.11, and above the 200-day MA of 0.09, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 45.92 is Neutral, neither overbought nor oversold. The STOCH value of 63.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0401.
Wanjia Group Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$6.36B | 19.61 | 6.83% | 2.72% | 29.81% | 10.40% | |
68 Neutral | HK$104.80M | 5.39 | 10.73% | 1.89% | 27.91% | 18.87% | |
66 Neutral | HK$1.82B | 20.84 | 4.85% | 3.81% | 0.33% | -44.28% | |
60 Neutral | HK$627.48M | 7.99 | 7.98% | 8.03% | ― | ― | |
54 Neutral | HK$126.61M | -18.49 | -17.12% | ― | -4.50% | 75.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | HK$721.31M | -5.63 | 476.63% | ― | -17.39% | -45.76% |
* Healthcare Sector Average
HK:0401
Wanjia Group Holdings Ltd.
0.11
0.07
151.11%
HK:0673
China Health Group
0.52
0.36
225.00%
HK:1931
IVD Medical Holding Limited
1.12
-0.58
-34.12%
HK:2192
Medlive Technology Co., Ltd.
8.61
-0.89
-9.37%
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
5.81
-1.31
-18.40%
HK:8372
Grand Brilliance Group Holdings Limited
0.13
0.03
35.05%
Wanjia Group Holdings Ltd. Corporate Events
Wanjia Group Raises HK$40.8 Million Through Fully Placed Rights Issue
Mar 31, 2026
Wanjia Group Holdings completed a rights issue of one new share for every existing share, which was initially under-subscribed, with valid applications covering about 54% of the offered shares. The remaining 45.98% of unsubscribed rights shares, t...
Wanjia Group’s Rights Issue Undersubscribed, Triggering Compensatory Placing
Mar 19, 2026
Wanjia Group Holdings reported the results of its rights issue, launched on the basis of one rights share for every one share held on the record date, with 560,222,136 rights shares offered in total. As of the acceptance deadline on 12 March 2026,...
Wanjia Group strengthens board with new independent non-executive director
Mar 2, 2026
Wanjia Group Holdings Limited, a Cayman Islands-incorporated company listed on the Hong Kong Stock Exchange, maintains standard Hong Kong corporate governance structures with dedicated audit, remuneration, and nomination and corporate governance c...
Wanjia Group Sets Out Board and Committee Line-up
Mar 2, 2026
Wanjia Group Holdings Limited has outlined the current composition of its board, naming Wang Jia Jun as the sole executive director and chief executive officer, alongside one non-executive director and four independent non-executive directors. The...
Wanjia Group Clears EGM Hurdle for Rights Issue With Poll Approval
Feb 10, 2026
Wanjia Group Holdings Ltd. announced that all resolutions put to shareholders at its extraordinary general meeting on 10 February 2026 were approved by poll. The meeting concerned, among other matters, a proposed rights issue, for which major shar...
Wanjia Group Calls 2026 EGM to Approve Capital Expansion and Rights Issue
Jan 20, 2026
Wanjia Group Holdings Ltd. has called an extraordinary general meeting (EGM) for 10 February 2026 in Hong Kong, where shareholders will vote on key capital measures. The board is seeking approval to double the company’s authorised share capi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.